{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:21:16Z","timestamp":1790706076211,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12149-022-01807-8","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T03:02:51Z","timestamp":1668049371000},"page":"99-107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparison of 1-h with 3-h planar 99mTc-pyrophosphate scintigraphy in patients with suspected transthyretin cardiac amyloidosis using SPECT as a reference standard"],"prefix":"10.1007","volume":"37","author":[{"given":"Toshinori","family":"Saitou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1786-0176","authenticated-orcid":false,"given":"Tadao","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Oyama-Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"1807_CR1","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","volume":"75","author":"M Hanna","year":"2020","unstructured":"Hanna M, Ruberg FL, Maurer MS, Dispenzieri A, Dorbala S, Falk RH, et al. Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week. J Am Coll Cardiol. 2020;75:2851\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"1807_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"S Bokhari","year":"2013","unstructured":"Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6:195\u2013201.","journal-title":"Circ Cardiovasc Imaging"},{"key":"1807_CR3","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","volume":"26","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26:2065\u2013123.","journal-title":"J Nucl Cardiol"},{"key":"1807_CR4","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","volume":"1","author":"A Castano","year":"2016","unstructured":"Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1:880\u20139.","journal-title":"JAMA Cardiol"},{"key":"1807_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12350-020-02328-5","volume":"28","author":"T Asif","year":"2021","unstructured":"Asif T, Gomez J, Singh V, Doukky R, Nedeltcheva A, Malhotra S. Comparison of planar with tomographic pyrophosphate scintigraphy for transthyretin cardiac amyloidosis: perils and pitfalls. J Nucl Cardiol. 2021;28:104\u201311.","journal-title":"J Nucl Cardiol"},{"key":"1807_CR6","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","volume":"15","author":"DF Hutt","year":"2014","unstructured":"Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15:1289\u201398.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1807_CR7","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/ejhf.2504","volume":"24","author":"M Merlo","year":"2022","unstructured":"Merlo M, Pagura L, Porcari A, Cameli M, Vergaro G, Musumeci B, et al. Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from phase 2 of the AC-TIVE study, an Italian nationwide survey. Eur J Heart Fail. 2022;24:1377\u201386.","journal-title":"Eur J Heart Fail"},{"key":"1807_CR8","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1253\/circj.CJ-19-0255","volume":"83","author":"K Marume","year":"2019","unstructured":"Marume K, Takashio S, Nishi M, Hirakawa K, Yamamoto M, Hanatani S, et al. Combination of commonly examined parameters is a useful predictor of positive 99mTc-labeled pyrophosphate scintigraphy findings in elderly patients with suspected transthyretin cardiac amyloidosis. Circ J. 2019;83:1698\u2013708.","journal-title":"Circ J"},{"key":"1807_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13550-018-0447-8","volume":"8","author":"S Furuya","year":"2018","unstructured":"Furuya S, Manabe O, Ohira H, Hirata K, Aikawa T, Naya M, et al. Which is the proper reference tissue for measuring the change in FDG PET metabolic volume of cardiac sarcoidosis before and after steroid therapy? EJNMMI Res. 2018;8:94.","journal-title":"EJNMMI Res"},{"key":"1807_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.010249","volume":"13","author":"A Masri","year":"2020","unstructured":"Masri A, Bukhari S, Ahmad S, Nieves R, Eisele YS, Follansbee W, et al. Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging. 2020;13: e010249.","journal-title":"Circ Cardiovasc Imaging"},{"key":"1807_CR11","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1007\/s12350-020-02205-1","volume":"27","author":"C R\u00e9gis","year":"2020","unstructured":"R\u00e9gis C, Harel F, Martineau P, Gr\u00e9goire J, Abikhzer G, Juneau D, et al. Tc-99m-pyrophosphate scintigraphy for the diagnosis of ATTR cardiac amyloidosis: comparison of quantitative and semi-quantitative approaches. J Nucl Cardiol. 2020;27:1808\u201315.","journal-title":"J Nucl Cardiol"},{"key":"1807_CR12","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1007\/s12350-017-1166-7","volume":"26","author":"BW Sperry","year":"2019","unstructured":"Sperry BW, Gonzalez MH, Brunken R, Cerqueira MD, Hanna M, Jaber WA. Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis. J Nucl Cardiol. 2019;26:1630\u20137.","journal-title":"J Nucl Cardiol"},{"key":"1807_CR13","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1007\/s00259-007-0596-x","volume":"34","author":"C Als","year":"2007","unstructured":"Als C. Optimizing patient throughput in nuclear medicine: a semi-quantitative tool for scheduling bone scintigraphy. Eur J Nucl Med Mol Imaging. 2007;34:2145\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-022-01807-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-022-01807-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-022-01807-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:45:42Z","timestamp":1744206342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-022-01807-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1807"],"URL":"https:\/\/doi.org\/10.1007\/s12149-022-01807-8","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"assertion":[{"value":"30 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Noriko Oyama-Manabe acts as a consultant to Canon Medical Systems and received payment for lectures from Philips Medical Systems, Eisai, Bayer Healthcare, GE Healthcare Pharma, and Canon Medical Systems. The other authors declare no financial conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the ethics committee of Hokkaido Cardiovascular Hospital (IRB No. 2021-2). The requirement of written informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}